FDA approvals in November include Lilly’s Zepbound for chronic weight management, plus AstraZeneca’s first-in-class Truqap for advanced forms of HR+ breast cancer. Bristol Myers Squibb’s Augtyro is approved for ROS1-positive non-small cell lung cancer, and Takeda’s Fruzaqla is okayed for metastatic colorectal cancer. Zituvimet is a new oral combo option for type 2 diabetes and Ogsiveo is cleared for aggressive desmoid tumors. Plus, Adzynma is the first treatment for cTTP, a rare blood clotting disorder.